16 October 2024 US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity.
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
Shares of UK clinical stage drug development company Evgen Pharma (AIM: EVG) were down more than 8% at 2.94 pence mid-morning, after it revealed that JuvLife Ltd, a division of Juvenescence, has terminated the patent and know-how license agreement for Evgen's Sulforadex sulforaphane stabilization technology. 2 August 2023
US biopharma company Vertex Pharmaceuticals has reported consolidated financial results for the second quarter ended June 30, 2023 and updated its full year 2023 financial guidance. 2 August 2023
While its work on the novel coronavirus swept Pfizer to the top of the world’s largest drugmakers by revenue, the firm must now find a way to manage a precipitous drop in sales, as countries move past the acute phase of the pandemic. 1 August 2023
US pharma giant Merck & Co today announced financial results for the second quarter of 2023 that topped expectations on strong sales of its blockbuster cancer drug Keytruda (pembrolizumab) and HPV vaccine Gardasil. 1 August 2023
Bimervax, the COVID-19 vaccine developed by Spanish company HIPRA Human Health, has today been authorized by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). 1 August 2023
Belgian women’s healthcare company Mithra Pharmaceuticals saw its shares gain 13.9% to 1.96 euros, after it revealed it has signed licensing agreement with privately-held Canadian specialty pharma firm Searchlight Pharma for the Canadian rights to Donesta. 1 August 2023
Age-related and autoimmune disease specialist MyMD Pharmaceuticals has announced positive Phase II data for its oral TNF-α inhibitor, MYMD-1. 1 August 2023
Russian drugmaker Nanolek is aiming to become the largest supplier of drugs for state needs this year, The Pharma Letter’s local correspondent reports 1 August 2023
Israeli biotech RedHill Biopharma has had its COVID-19 candidate RHB-107 accepted for inclusion in a US government-funded project to test products for the outpatient treatment of people with coronavirus. 31 July 2023
Change is in the air for the Indian clinical trial market. The rapid approval of COVID-19 vaccinations during the SARS-CoV-2 pandemic illustrated the value of clinical studies that could improve therapeutic regimens, and advance evidence-based medicine. 31 July 2023
Having abandoned direct advertising of their drugs in Russia after the outbreak of hostilities in Ukraine, global drugmakers are now continuing active spending on the promotion of their products through medical organizations, allocating funds for research and industry events, reports The Pharma Letter’s local correspondent. 31 July 2023
Japanese drugmakers Sumitomo Pharma and Otsuka Pharmaceutical have announced negative results from the DIAMOND and DIAMOND 2 trials of ulotaront. 31 July 2023
Swiss rare diseases specialist Santhera Pharmaceuticals says it has fully divested Raxone (idebenone) for all indications to Italian family-owned drugmaker Chiesi Group, replacing the 2019 agreement between the companies. 31 July 2023
Shares of Ionis Pharmaceuticals closed up 3.3% at $39.79 on Friday, after the US RNA-targeted drug developer revealed it has expanded its existing collaboration with AstraZeneca to include exclusive rights for the UK pharma major to commercialize eplontersen in Latin America 31 July 2023
A team of researchers, including German Institute for Quality and Efficiency in Health Care (IQWiG) biometrician Ralf Bender, has demonstrated that shortcomings in the documentation of time-to-event outcomes in clinical trials also affect systematic reviews. 31 July 2023
AstraZeneca has reported total revenues of $11.4 billion in the second quarter of 2023, a rise of around 6%, beating expectations from most analysts. 28 July 2023
As the first obesity drug to be approved in Japan in the last three decades, Danish diabetes giant Novo Nordisk’s Wegovy (semaglutide) is expected to bring a substantial shift in the treatment approach. 28 July 2023
More positive data for Eli Lilly’s weight loss candidate tirzepatide will boost interest in the product, as the US regulator warns of supply shortages at certain doses. 28 July 2023
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.